Maribavir for Prevention of CMV After Stem Cell Transplants
Public ClinicalTrials.gov record NCT00223925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
Study identification
- NCT ID
- NCT00223925
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2004
- Primary completion
- Apr 4, 2006
- Completion
- Apr 4, 2006
- Last update posted
- May 12, 2021
2004 – 2006
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | — | — |
| UCLA Medical Center | Los Angeles | California | — | — |
| Loyola University | Maywood | Illinois | — | — |
| Tufts-New England Medical Center | Boston | Massachusetts | — | — |
| Wayne State Medical Center | Detroit | Michigan | — | — |
| University of Minnesota | Minneapolis | Minnesota | — | — |
| Washington University School of Medicine | St Louis | Missouri | — | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | — | — |
| Duke Medical Center | Durham | North Carolina | — | — |
| Baylor University Medical Center | Dallas | Texas | — | — |
| MD Anderson Cancer Center | Houston | Texas | — | — |
| University of Utah | Salt Lake City | Utah | — | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00223925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00223925 live on ClinicalTrials.gov.